Menü
Das neue sharewise ist da Übersichtlicher, schneller, mit heller und dunkler Ansicht — und allem, was du kennst. Jetzt ausprobieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Suchergebnisse

Delta Expands Seattle-Tokyo Network With New Narita Service
Delta Expands Seattle-Tokyo Network With New Narita Service

Delta Air Lines’ DAL launch of daily nonstop service between Seattle and Tokyo-Narita, beginning March 27, 2027, is expected to strengthen its position in the Pacific Northwest and expand

Here's How Ross Stores Stock is Poised Ahead of Q2 Earnings
Here's How Ross Stores Stock is Poised Ahead of Q2 Earnings

Ross Stores, Inc. ROST is likely to post year-over-year top and bottom-line growth when it reports second-quarter fiscal 2026 earnings on Aug. 20, after market close. The Zacks Consensus Estimate

Accelerant Q2 Earnings Beat Estimates on Strong Premium Growth
Accelerant Q2 Earnings Beat Estimates on Strong Premium Growth

Accelerant Holdings ARX reported second-quarter fiscal 2026 adjusted earnings of 32 cents per share, which more than doubled from 13 cents reported in the year-ago quarter. The bottom line beat the

Intellicheck Mobilisa, Inc. (IDN) Matches Q2 Earnings Estimates
Intellicheck Mobilisa, Inc. (IDN) Matches Q2 Earnings Estimates

Intellicheck Mobilisa, Inc. (IDN) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.01 per share a year ago. These

WidePoint (WYY) Q2 Earnings Meet Estimates
WidePoint (WYY) Q2 Earnings Meet Estimates

WidePoint (WYY) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.06 per share a year ago. These figures are adjusted for

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.04 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.98 per share a year ago. These